PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection.